Coherus Oncology Shares Outstanding History (CHRS)
Coherus Oncology reported 121.2M shares outstanding at the end of fiscal 2025.
View full Coherus Oncology company overviewCoherus Oncology annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 121.2M | 5.5M | +4.79% |
| 2024 | 2024-12-31 | 115.6M | 3.4M | +3.03% |
| 2023 | 2023-12-31 | 112.2M | 33.4M | +42.31% |
| 2022 | 2022-12-31 | 78.9M | 1.9M | +2.50% |
| 2021 | 2021-12-31 | 76.9M | 4.4M | +6.09% |
| 2020 | 2020-12-31 | 72.5M | 2.1M | +3.05% |
| 2019 | 2019-12-31 | 70.4M | 2.1M | +3.02% |
| 2018 | 2018-12-31 | 68.3M | 8.5M | +14.14% |
| 2017 | 2017-12-31 | 59.8M | 14.0M | +30.63% |
| 2016 | 2016-12-31 | 45.8M | 6.8M | +17.44% |
| 2015 | 2015-12-31 | 39.0M | 5.7M | +17.28% |
| 2014 | 2014-12-31 | 33.3M | 28.4M | +587.47% |
| 2013 | 2013-12-31 | 4.8M | — | — |
Coherus Oncology quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 154.5M | 38.2M | +32.91% |
| Q1 2026 | 2026-03-31 | 154.2M | 38.3M | +33.05% |
| Q4 2025 | 2025-12-31 | 121.2M | 5.5M | +4.79% |
| Q3 2025 | 2025-09-30 | 116.2M | 1.0M | +0.89% |
| Q2 2025 | 2025-06-30 | 116.2M | 1.0M | +0.89% |
| Q1 2025 | 2025-03-31 | 115.9M | 2.4M | +2.12% |
| Q4 2024 | 2024-12-31 | 115.6M | 3.4M | +3.03% |
| Q3 2024 | 2024-09-30 | 115.2M | 6.1M | +5.59% |
| Q2 2024 | 2024-06-30 | 115.2M | 20.8M | +21.98% |
| Q1 2024 | 2024-03-31 | 113.5M | 33.0M | +41.01% |
| Q4 2023 | 2023-12-31 | 112.2M | 33.4M | +42.31% |
| Q3 2023 | 2023-09-30 | 109.1M | 31.3M | +40.30% |
| Q2 2023 | 2023-06-30 | 94.4M | 16.7M | +21.54% |
| Q1 2023 | 2023-03-31 | 80.5M | 3.2M | +4.07% |
| Q4 2022 | 2022-12-31 | 78.9M | 1.9M | +2.50% |
| Q3 2022 | 2022-09-30 | 77.8M | 1.2M | +1.55% |
| Q2 2022 | 2022-06-30 | 77.7M | 1.2M | +1.62% |
| Q1 2022 | 2022-03-31 | 77.3M | 4.2M | +5.76% |
| Q4 2021 | 2021-12-31 | 76.9M | 4.4M | +6.09% |
| Q3 2021 | 2021-09-30 | 76.6M | 6.2M | +8.83% |
| Q2 2021 | 2021-06-30 | 76.5M | 8.2M | +11.95% |
| Q1 2021 | 2021-03-31 | 73.1M | 13.3M | +22.20% |
| Q4 2020 | 2020-12-31 | 72.5M | 26.7M | +58.30% |
| Q4 2019 | 2019-12-31 | 70.4M | 31.4M | +80.40% |
| Q4 2018 | 2018-12-31 | 68.3M | 35.0M | +105.37% |
| Q4 2017 | 2017-12-31 | 59.8M | 26.6M | +79.93% |
| Q4 2016 | 2016-12-31 | 45.8M | 12.6M | +37.74% |
| Q4 2015 | 2015-12-31 | 39.0M | 5.7M | +17.28% |
| Q3 2015 | 2015-09-30 | 33.3M | 28.6M | +619.18% |
| Q2 2015 | 2015-06-30 | 33.3M | 28.4M | +587.47% |
| Q1 2015 | 2015-03-31 | 33.3M | — | — |
| Q4 2014 | 2014-12-31 | 33.3M | — | — |
| Q3 2014 | 2014-09-30 | 4.6M | — | — |
| Q4 2013 | 2013-12-31 | 4.8M | — | — |
Coherus Oncology shares outstanding trends
Over the last five reported fiscal years, Coherus Oncology's shares outstanding moved from 72.5M to 121.2M, a change of 48.6M. The latest reported quarter, Q2 2026, shows 154.5M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coherus Oncology filings at SEC.gov ↗